Actelion to enter Phase II clinical development with new dual orexin receptor...
(Source: Actelion Ltd) Investor webcast to provide background information on Actelion's new DORA to be broadcast 07 July 2016 at 14:00 hrs CEST ALLSCHWIL, SWITZERLAND - 07 July 2016 - Actelion Ltd...
View ArticleVery strong performance in the first half of 2016 - enhanced by successful...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 21 July 2016- Actelion Ltd (SIX: ATLN) today announced its results for the first six months of 2016. OPERATING HIGHLIGHTS Excellent Opsumit...
View ArticleActelion presents outstanding 2015 results - Company transformation...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 09 February 2016- Actelion Ltd (SIX: ATLN) today announced its results for the full year 2015. OPERATING HIGHLIGHTS Opsumit - Strong, sustained...
View ArticleThe New England Journal of Medicine publishes "Selexipag for the treatment of...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 23 December 2015 - Actelion (SIX: ATLN) announced today that the New England Journal of Medicine (NEJM) has published the results of the oral, selective...
View ArticleFurther data on selexipag (Uptravi) and macitentan (Opsumit) to be presented...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 13 May 2015 - Actelion Ltd (SIX: ATLN) today announced that key data from the pivotal Phase III GRIPHON study with the investigational drug selexipag...
View ArticleSelexipag (Uptravi) long-term outcome data in pulmonary arterial hypertension...
(Source: Actelion Ltd) Selexipag significantly reduced the risk of a morbidity/mortality event by 40% versus placebo (p Selexipag improved long-term outcomes in an investigational trial of patients...
View ArticleActelion's Chief Scientific Officer Martine Clozel awarded the Tomoh Masaki...
(Source: Actelion Ltd) SAVANNAH, UNITED STATES OF AMERICA AND ALLSCHWIL, SWITZERLAND - 05 September 2015 - Actelion Ltd (SIX: ATLN) today announced that its Chief Scientific Officer and Member of the...
View ArticleActelion announces commercial availability of Uptravi (selexipag) in Germany...
(Source: Actelion Ltd) Market authorization for treatment of pulmonary arterial hypertension granted by European Commission on 12 May 2016 Uptravi available for patients in Germany as of 15 June 2016...
View ArticleActelion announces US commercial availability of UPTRAVI (selexipag) as of 4...
(Source: Actelion Ltd) UPTRAVI - FDA approved on 21 December 2015 for treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression and reduce the risk of hospitalization...
View ArticleActelion receives approval for Uptravi (selexipag) for the treatment of...
(Source: Actelion Ltd) Approval granted by Medsafe in New Zealand on 17 March 2016 and by the TGA in Australia on 18 March 2016 ALLSCHWIL, SWITZERLAND - 22 March 2016 - Actelion Ltd (SIX: ATLN)...
View ArticleActelion receives Health Canada approval for Uptravi (selexipag) for the...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 26 January 2016 - Actelion (SIX: ATLN) announced today that Health Canada has granted a Notice of Compliance (NOC) approving the orally active, selective...
View ArticleActelion is granted marketing authorization for Uptravi (selexipag) in...
(Source: Actelion Ltd) Marketing authorization granted by European Commission on 12 May 2016 First European Union (EU) market introduction to commence in the near future ALLSCHWIL, SWITZERLAND - 17 May...
View ArticleActelion delivers excellent results in the first quarter 2015 (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 21 April 2015- Actelion Ltd (SIX: ATLN) today announced its results for the first quarter of 2015. OPERATING HIGHLIGHTS Opsumit (macitentan) - Q1...
View ArticleActelion advances clinical development of its specialty immunology pipeline...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 16 April 2015 - Actelion Ltd (SIX: ATLN) announced today that it is accelerating its clinical development efforts in the field of immunological...
View ArticleActelion receives positive CHMP opinion for Uptravi (selexipag) for the...
(Source: Actelion Ltd) The European Commission is expected to make a final decision within 67 days. ALLSCHWIL, SWITZERLAND - 29 January 2016 - Actelion (SIX: ATLN) announced today that the Committee...
View ArticleActelion receives US FDA approval of Uptravi (selexipag) for the treatment of...
(Source: Actelion Ltd) Uptravi approved for treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression and reduce the risk of hospitalization for PAH Uptravi will be...
View ArticleActelion delivers excellent first half 2015 results (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 21 July 2015- Actelion Ltd (SIX: ATLN) today announced its results for the first six months of 2015. OPERATING HIGHLIGHTS Opsumit® - Sales of CHF...
View ArticleVery strong performance continues in the first quarter of 2016 - driven by...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 21 April 2016- Actelion Ltd (SIX: ATLN) today announced its results for the first three months of 2016. OPERATING HIGHLIGHTS Excellent Opsumit...
View ArticleActelion initiates Phase III study to evaluate macitentan (Opsumit) in...
(Source: Actelion Ltd) Phase III study TOMORROW aims to show the long-term benefits of macitentan (Opsumit) in children with pulmonary arterial hypertension (PAH) Global program has received...
View ArticleActelion delivers strong nine months results (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 20 October 2015 - Actelion Ltd (SIX: ATLN) today announced its results for the first nine months of 2015. OPERATING HIGHLIGHTS Opsumit (macitentan)...
View ArticleActelion to present at upcoming investor conferences - Actelion 2015-2020 -...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 11 January 2016- Actelion Ltd (SIX: ATLN) announced today that representatives from Actelion will present at upcoming investor conferences....
View ArticleActelion receives Swissmedic approval for Uptravi (selexipag) for treatment...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 16 August 2016- Actelion Ltd (SIX: ATLN) announced today that Swissmedic has granted approval for the orally active, selective IP prostacyclin...
View ArticleNew scientific publications highlight the unique profile of Actelion's...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 17 October 2016 - Actelion Ltd (SIX: ATLN) announced today that a series of recently published scientific articles [1,2,3,4,5] describing the...
View ArticleActelion to investigate all-oral combination therapy for patients with...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 29 September 2016 - Actelion Ltd (SIX: ATLN) announced today that it will investigate the use of combination therapy with ponesimod and dimethyl...
View ArticleExcellent operational results - supported by outstanding Uptravi launch -...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 20 October 2016- Actelion Ltd (SIX: ATLN) today announced its results for the first nine months of 2016. OPERATING HIGHLIGHTS Strong Opsumit...
View ArticleActelion announces positive results of the MERIT study with macitentan in...
Actelion will host an investor conference call and webcast to discuss the MERIT results and provide an update on its cardiovascular pipeline at 14:00 hrs CET ALLSCHWIL/BASEL, SWITZERLAND - 07 November...
View ArticleActelion announces positive results of the MERIT study with macitentan in...
(Source: Actelion Ltd) Actelion will host an investor conference call and webcast to discuss the MERIT results and provide an update on its cardiovascular pipeline at 14:00 hrs CET ALLSCHWIL/BASEL,...
View ArticleActelion to provide an update on advancements in its cardiovascular pipeline...
ALLSCHWIL/BASEL, SWITZERLAND - 07 November 2016 - Actelion Ltd (SIX: ATLN) announced that the company will provide an update on its cardiovascular activities today (Monday, 07 November) in an investor...
View ArticleActelion to provide an update on advancements in its cardiovascular pipeline...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 07 November 2016 - Actelion Ltd (SIX: ATLN) announced that the company will provide an update on its cardiovascular activities today (Monday, 07...
View ArticleActelion announces results of the MAESTRO study with macitentan in patients...
ALLSCHWIL/BASEL, SWITZERLAND - 23 January 2017 - Actelion Ltd (SIX: ATLN) today announced that the MAESTRO study to assess the efficacy, safety and tolerability of macitentan in patients with pulmonary...
View ArticleActelion announces results of the MAESTRO study with macitentan in patients...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 23 January 2017 - Actelion Ltd (SIX: ATLN) today announced that the MAESTRO study to assess the efficacy, safety and tolerability of macitentan in...
View ArticleActelion announces excellent financial results for 2016
ALLSCHWIL/BASEL, SWITZERLAND - 14 February 2017 - Actelion Ltd (SIX: ATLN) today announced its results for the full year 2016. FINANCIAL HIGHLIGHTS Sales growing to CHF 2,412 million (+15% at CER)...
View ArticleActelion announces excellent financial results for 2016 (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 14 February 2017- Actelion Ltd (SIX: ATLN) today announced its results for the full year 2016. FINANCIAL HIGHLIGHTS Sales growing to CHF 2,412...
View ArticleActelion receives marketing approval for Opsumit (macitentan) in pulmonary...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 26 March 2015 - Actelion (SIX: ATLN) announced today that Japan's Ministry of Health, Labor and Welfare granted marketing approval for Opsumit®...
View ArticlePublication of Idorsia's prospectus relating to the listing of Idorsia Ltd on...
ALLSCHWIL/BASEL, SWITZERLAND- 09 June 2017 -Actelion Ltd (SIX:ATLN) today published the listing prospectus relating to the listing of Idorsia shares on SIX Swiss Exchange. With the tender offer for all...
View ArticleActelion provides an update on the progress towards launching Idorsia - Key...
Positive dose-finding results with ACT-132577 - asset to progress to Phase 3 development in resistant hypertension Positive safety study with cenerimod - asset to progress into larger Phase 2...
View ArticleActelion provides an update on the progress towards launching Idorsia - Key...
Positive dose-finding results with ACT-132577 - asset to progress to Phase 3 development in resistant hypertension Positive safety study with cenerimod - asset to progress into larger Phase 2...
View ArticleAdditional data on selexipag (Uptravi) and macitentan (Opsumit) to be...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 27 August 2015 - Actelion Ltd (SIX: ATLN) today announced that key data from the pivotal Phase III GRIPHON study with the investigational drug selexipag...
View ArticleActelion provides an update on the Phase III IMPACT program with cadazolid in...
ALLSCHWIL, SWITZERLAND - 08 June 2017 - Actelion Ltd (SIX: ATLN) today provided an update on the Phase III program IMPACT to investigate the efficacy and safety of Actelion's novel anti-infective...
View ArticleNew data supporting gradual up-titration of ponesimod to mitigate first-dose...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 25 June 2015 - Actelion Ltd (SIX: ATLN) today announced that data supporting a gradual up-titration dose regimen of ponesimod will be presented at the...
View ArticleActelion announces changes to its executive team upon completion of the...
ALLSCHWIL/BASEL, SWITZERLAND- 14 June 2017 - Actelion Ltd (SIX: ATLN) today announced changes to its executive team that will take effect upon the settlement of the public tender offer by Johnson &...
View ArticleJohnson & Johnson to Acquire Actelion for $30 Billion With Spin-Out of New...
(Source: Janssen Pharmaceuticals Inc) Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D Company for...
View ArticleCORRECTION: JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH...
In the previous press release the companies omitted the cash amount with which R&D NewCo will launch. This has now been rectified and noted as CHF 1 billion. Actelion Shareholders to Receive $280...
View ArticleJOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH SPIN-OUT OF NEW...
For Immediate Release� Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D Company for Each Actelion...
View ArticleCORRECTION: JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH...
(Source: Actelion Ltd) In the previous press release the companies omitted the cash amount with which R&D NewCo will launch. This has now been rectified and noted as CHF 1 billion. Actelion...
View ArticleJOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH SPIN-OUT OF NEW...
(Source: Actelion Ltd) For Immediate Release Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D...
View ArticleActelion emphasizes commitment to advance research and care in rare diseases...
(Source: Actelion Ltd) 'Patient Voice - Join us in making the voice of rare diseases heard.' This is the theme of Rare Disease Day 2016 - and a cause for Actelion to emphasize its long-term commitment...
View Article